The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment by RAFFAELE M et al.
Original Article
The Ubiquitin-Proteasome System and Inflammatory
Activity in Diabetic Atherosclerotic Plaques
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The role of ubiquitin-proteasome system in the accelerated
atherosclerotic progression of diabetic patients is unclear.
We evaluated ubiquitin-proteasome activity in carotid
plaques of asymptomatic diabetic and nondiabetic pa-
tients, as well as the effect of rosiglitazone, a peroxisome
proliferator–activated receptor (PPAR)- activator, in di-
abetic plaques. Plaques were obtained from 46 type 2
diabetic and 30 nondiabetic patients undergoing carotid
endarterectomy. Diabetic patients received 8 mg rosiglita-
zone (n  23) or placebo (n  23) for 4 months before
scheduled endarterectomy. Plaques were analyzed for mac-
rophages (CD68), T-cells (CD3), inflammatory cells (HLA-
DR), ubiquitin, proteasome 20S activity, nuclear factor
(NF)-B, inhibitor of B (IB)-, tumor necrosis factor
(TNF)-, nitrotyrosine, matrix metalloproteinase (MMP)-
9, and collagen content (immunohistochemistry and en-
zyme-linked immunosorbent assay). Compared with non-
diabetic plaques, diabetic plaques had more macrophages,
T-cells, and HLA-DR cells (P < 0.001); more ubiquitin,
proteasome 20S activity (TNF-), and NF-B (P < 0.001);
and more markers of oxidative stress (nitrotyrosine and
O2
 production) and MMP-9 (P < 0.01), along with a lesser
collagen content and IB- levels (P < 0.001). Compared
with placebo-treated plaques, rosiglitazone-treated dia-
betic plaques presented less inflammatory cells (P < 0.01);
less ubiquitin, proteasome 20S, TNF-, and NF-B (P <
0.01); less nitrotyrosine and superoxide anion production
(P < 0.01); and greater collagen content (P < 0.01),
indicating a more stable plaque phenotype. Similar findings
were obtained in circulating monocytes obtained from the
two groups of diabetic patients and cultured in the pres-
ence or absence of rosiglitazone (7.0 mol/l). Ubiquitin-
proteasome over-activity is associated with enhanced
inflammatory reaction and NF-B expression in diabetic
plaques. The inhibition of ubiquitin-proteasome activity in
atherosclerotic lesions of diabetic patients by rosiglita-
zone is associated with morphological and compositional
characteristics of a potential stable plaque phenotype,
possibly by downregulating NF-B-mediated inflammatory
pathways. Diabetes 55:622–632, 2006
Cardiovascular disease represents the leadingcause of death in patients with type 2 diabetes(1). Diabetes leads to increased vulnerability forplaque disruption and mediates increased inci-
dence and severity of clinical events (2). Inflammation,
particularly in diabetes, plays a central role in the cascade
of events that result in plaque erosion and fissuring (2).
There is emerging evidence that the ubiquitin-proteasome
system, the major pathway for nonlysosomal intracellular
protein degradation in eucaryotic cells, induces inflamma-
tion in both initial stage and progression of atherosclerosis
(3). The ubiquitin-mediated proteolytic pathway involves
the conjugation of multiple moieties of ubiquitin, a 76-
amino acid polypeptide, to cellular proteins in a multien-
zymatic process, targeting these proteins to degradation
(4). This ligation of ubiquitin by a series of ubiquitin-
conjugating enzymes produce polyubiquitin chains, which
serve as targeting signals for degradation of the protein by
the proteasome. The multicatalytic proteasome consists of
a central catalytic core, the 20S proteasome, and two
regulatory 19S complexes (5). Moreover, the ubiquitin-
proteasome pathway is required for activation of nuclear
factor kappa B (NF-B), a central transcription factor that
regulates inflammatory genes, by degradation of its inhib-
itory IB proteins (6). Although it has been demonstrated
that diabetes may upregulate ubiquitin-proteasome path-
way in rat muscle (7), still no evidence exists about the
potential role of ubiquitin-proteasome system in the evo-
lution of atherosclerotic plaques of diabetic patients. We
hypothesized that by increasing ubiquitin-proteasome ac-
tivity, diabetes may enhance the inflammatory potential of
atherosclerotic plaques favoring instability.
This study was designed to identify differences in in-
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flammatory infiltration as well as ubiquitin-proteasome
activity between carotid plaques of asymptomatic diabetic
and nondiabetic patients. Because experimental and
pathological studies suggest that activation of peroxisome
proliferator–activated receptor (PPAR)- may reduce in-
flammation (8) and inhibit ubiquitin-proteasome activity
(9), the study also evaluated the effect of the PPAR-
agonist rosiglitazone on ubiquitin-proteasome activity in
carotid plaques of diabetic patients.
RESEARCH DESIGN AND METHODS
The study group comprised 46 type 2 diabetic and 30 nondiabetic patients
(nondiabetic group) with asymptomatic carotid stenosis, enlisted to undergo
carotid endarterectomy for extracranial high-grade (70%) internal carotid
artery stenosis (10). Diabetes was categorized according to American Diabe-
tes Association criteria (11). The diabetic patients were randomized in a
double-blind fashion to receive rosiglitazone (4 mg b.i.d., n  23) or placebo
(n  23) for 4 months, according to human studies evaluating the carotid
arterial intima-media thickness progression as well as circulating markers of
inflammation after PPAR- agonist treatments (12,8). In the placebo group, the
dose of other concomitant hypoglycemic medication was changed to obtain a
similar profile of metabolic parameters. Additional antidiabetic therapy,
including sulfonylurea, metformin, and insulin, was titrated for optimal
glycemic control for 4 months. After the treatment period, all patients had
undergone endarterectomy. Fasting plasma glucose, insulin, and serum lipids,
as well as insulin resistance index (by homeostasis model assessment of
insulin resistance [HOMA-IR]) (13), were measured at baseline, monthly, and
before endarterectomy. Moreover, C-reactive protein (CRP) serum levels (by
enzyme-linked immunosorbent assay [ELISA]; Diagnostic Systems Labora-
tory) were measured at baseline and before endarterectomy in 12 patients
from the control group, 15 from the placebo group, and 16 from the
rosiglitazone group. Written informed consent was obtained from all patients
before each examination. The local ethics review committee approved the
study.
Atherectomy specimens. After surgery, the specimens were cut perpendic-
ular to the long axis into two halves. The first half was frozen in liquid nitrogen
for the following ELISA analysis. A portion of the other half specimen was
immediately immersion-fixed in 10% buffered formalin. Sections were serially
cut at 5 m, mounted on lysine-coated slides, and stained with hematoxylin
and eosin and with the trichrome method. Carotid artery specimens were
analyzed by light microscopy.
Immunohistochemistry. After the surgical procedure, samples were imme-
diately frozen in isopentane and cooled in liquid nitrogen. Similar regions of
the plaque were analyzed (Fig. 1). Serial sections were incubated with specific
antibodies: anti-ubiquitin, anti–proteasome 20S, anti–HLA-DR, anti-CD68, and
anti-CD3 (Dako); anti–IB- and anti-matrix metalloproteinase (MMP)-9
(Santa Cruz); and anti–tumor necrosis factor (TNF)- (R&D). Specific anti-
bodies that selectively recognize the activated form of NF-B (p65 and p50
subunits; Santa Cruz) were used. Analysis of immunohistochemistry was
performed with a personal computer-based quantitative 24-bit color image
analysis system (IM500; Leica Microsystem AG).
Biochemical assays. Plaques were lysed and centrifuged for 10 min at
10,000g at 4°C. After centrifugation, 20 g of each sample were loaded,
electrophoresed in polyacrylamide gel, and electroblotted onto a nitrocellu-
lose membrane. Each determination was repeated at least three times.
Ubiquitin, IB-, MMP-9, TNF-, and nitrotyrosine levels were quantified in
plaques using a specific ELISA kits (from Santa Cruz, R&D Systems, and
Imgenex). Nuclear extracts from plaque specimens were obtained as de-
scribed by Ohlsson et al. (14). We used a specific antibody that selectively
recognizes the activated form of the NF-B subunit p65. NF-B binding to B
sites was assessed using the Trans-AM NF-B p65 transcription factor assay
kit (Active Motif Europe; Rixensart). In this assay, an oligonucleotide con-
taining the NF-B consensus site is attached to a 96-well plate. The active form
of NF-B contained in cell extracts specifically binds to this oligonucleotide
and can be revealed by incubation with antibodies. Thereafter, whole-cell
extracts were prepared, and 10 g of total cellular proteins were analyzed for
p65 binding to B oligonucleotide according to the manufacturer’s instruc-
tions. In addition, we analyzed the expression of the activated p50 subunit by
specific Trans-AM NF-B p50 transcription factor assay kit (Active Motif;
Rixensart). For the quantitative measurement of the proteasome 20S activity,
a specific SDS activation kit (Boston Biochem) was used. Nitrotyrosine was
assayed into the plaque tissue with a kit supplied by Hycult Biotech.
Macrophages extraction from atherosclerotic plaques. Macrophages
were selectively extracted from plaques as described by de Vries et al. (15).
Biochemical assay on cell homogenates for ubiquitin and proteasome 20S
determinations were performed as illustrated earlier.
Measurement of O2
. Production of O2
 was measured as the superoxide
dismutase–inhibitable reduction of cytochrome c, as previously described (16)
Isolation and culture of blood monocytes. Peripheral blood monocytes
from 10 diabetic and 10 nondiabetic patients were purified and cultured as
described by Cipollone et al. (17). Monocytes from diabetic patients (24 	
106/4 ml of Dulbecco’s modified Eagle’s medium) were cultured in the
presence or absence of rosiglitazone (7.0 mol/l for 48 h) and in the presence
or absence of MG132 (10 mmol/l stock solutions in DMSO; Calbiochem), a
specific proteasome inhibitor (10 mol/l for 5 h). At the end of the incubation,
adherent monocytes were scraped, collected, and lysed, and ubiquitin, pro-
teasome 20S, NF-B, IB-, and O2
 production were evaluated.
Statistical analysis. Data are presented as mean
 SD. Continuous variables
were compared among the groups of patients with one-way ANOVA for
normally distributed data and Kruskal-Wallis for non–normally distributed
data. When differences were found among the groups, Bonferroni correction
was used to make pairwise comparisons. P 0.05 was considered statistically
significant. All calculations were performed using SPSS 12.
RESULTS
Demographic data for the study population are presented
in Table 1. Percentage of carotid diameter reduction, risk
factors, and concomitant nonhypoglycemic therapy did
not differ among the groups (Table 1). In diabetic patients,
mean plasma glucose between weeks 0 and 16 decreased
similarly with placebo (1.6 
 0.6 mmol/l, P  0.05) and
rosiglitazone (1.5 
 0.6 mmol/l, P  0.05), while HbA1c
FIG. 1. Representative example of plaques studied. This
section is representative of the plaque region analyzed. The
section was stained with hematoxylin-eosin. Plaque section
at low magnification.
R. MARFELLA AND ASSOCIATES
DIABETES, VOL. 55, MARCH 2006 623
(A1C) levels showed a trend to decrease in both groups
(0.83 
 0.4%, P  0.14, and 0.87 
 0.5%, P  0.16,
respectively). In the placebo group, glimepiride was tested
and its daily dose was adjusted in four patients to a range
of 1–6 mg/day. Metformin was adjusted during the study in
three patients; the daily dose range was 500–1,700 mg/day.
Insulin was adjusted in nine patients. HOMA-IR decreased
in the rosiglitazone group but remained unchanged in the
placebo group (1.1 
 0.3 vs. 0.4 
 0.2, P  0.01). In
diabetic patients, the decline in CRP was 0.12 mg/dl in
the placebo group and 0.42 mg/dl in the rosiglitazone
group (Table 2). No patient in either group developed any
clinical events during the study.
Plaque composition. Compared with nondiabetic pa-
tients, diabetic patients (all) had a significantly greater
portion of plaque area occupied by macrophages (19 
 5
vs. 5 
 2%; P  0.01) and T-cells (55 
 13 vs. 15 
 7%; P 
0.01), as well as greater expression of HLA-DR antigen
(25 
 5 vs.12 
 3%, P  0.01) (Table 1 and Fig. 2).
Compared with the placebo group, the rosiglitazone group
presented a significantly smaller portion of plaque area
occupied by macrophages (P  0.01) and T-cells (P 
0.01), as well as lower expression of HLA-DR (P  0.01)
(Table 1 and Fig. 2). Both immunohistochemistry and
ELISA revealed markedly higher staining and levels of
TNF- in all diabetic lesions compared with nondiabetic
lesions (P 0.001). In diabetic patients, staining and levels
of TNF- were significantly more abundant in lesions from
placebo than lesions from the rosiglitazone group (P 
0.001) (Fig. 2). MMP-9 levels were more abundant in
diabetic than in nondiabetic lesions (P  0.001); in dia-
betic patients, MMP-9 levels were more abundant in le-
sions from the placebo group than those from the
rosiglitazone group (P  0.001). Lower content of intersti-
tial collagen was found in plaques of all diabetic patients
compared with nondiabetic patients. Content of interstitial
collagen of plaques from rosiglitazone-treated patients
was higher compared with that from placebo-treated pa-
tients (P  0.01) (Fig. 2).
Ubiquitin-proteasome activity. Immunohistochemistry
revealed higher staining of ubiquitin and proteasome 20S
in diabetic inflammatory cells than in nondiabetic inflam-
matory cells (P  0.01), with the highest staining detected
in patients randomized to placebo. A similar pattern of
response was seen for ubiquitin plaque levels (P  0.001)
and proteasome 20S plaque activity (P  0.001) (Fig. 3).
Ubiquitin and proteasome 20S in macrophages ex-
tracted from plaques. To identify whether the higher
ubiquitin-proteasome levels observed in diabetic plaques
were produced by macrophages, we repeated quantitative
TABLE 1
Characteristics of study patients
Variables Control group Placebo group Rosiglitazone group
n 30 23 23
Age (years) 69
 2 68
 3 69 
 2
Male 16 (53.3) 13 (56.5) 12 (52.2)
Patients characteristics
Family history of IHD 14 (46.7) 13 (56.5) 16 (69.6)
Hypertension 15 (50) 11 (47.8) 10 (43.5)
Hypercholesterolemia 13 (43.3) 10 (43.5) 9 (39.1)
Cigarette smoking 12 (40) 7 (30.4) 8 (34.8)
Coronary artery disease 13 (43.3) 14 (60.9) 16 (69.6)
BMI (kg/m2) 27.6 
 2 28.2
 2 28.9
 3
Systolic blood pressure (mmHg) 128
 12 129
 11 130
 12
Diastolic blood pressure (mmHg) 81
 4 81
 4 82 
 3
A1C (%) 4.9
 1.1*† 8.1
 1.4 8.2
 1.5
Blood glucose (mmol/l) 6
 0.9*† 9.7
 1.4 9.6
 1.3
Insulin (U/ml) 8.06
 3.3*† 10.6
 2.4 10.8
 2.7
HOMA-IR 2.15
 0.9*† 4.57
 1.3 4.61
 1.3
CRP (mg/dl) 0.86
 0.09*† 1.22
 0.08 1.19
 0.09
Total cholesterol (mmol/l) 5.64
 0.09 5.63
 0.09 5.67
 0.10
HDL cholesterol (mmol/l) 1.26
 0.10 1.22
 0.08 1.21
 0.09
Triglycerides (mmol/l) 1.94
 0.33 1.95
 0.31 1.97
 0.34
Stenosis severity (%) 75.5
 4.9 76.4
 4.5 76.2
 3.8
Macrophage-rich areas (%) 5
 2*† 24
 5 14 
 6*
T-cells per mm2 section area 15 
 7*† 70
 13 41
 12*
HLA-DR (%) 12
 3*† 31
 5 19 
 6*
Active therapy
Aspirin 24 (80) 21 (91.3) 20 (86.9)
Warfarin 2 (6.6) 1 (4.3) 1 (4.3)
-Blocker 7 (23.3) 5 (21.7) 5 (21.7)
Calcium-channel blocker 3 (10) 4 (17.4) 3 (13.1)
Statin 20 (66.6) 17 (73.9) 16 (69.6)
ACE inhibitor 16 (53.3) 14 (60.9) 12 (52.1)
Diuretic agent 9 (30) 6 (26.1) 7 (30.4)
AT-2 antagonist 14 (46.6) 12 (52.1) 11 (48.7)
Insulin — 16 (69.6) 17 (73.9)
Sulfonylureas — 8 (34.8) 7 (30.4)
Metformin — 6 (26.1) 5 (21.7)
Data are means 
 SD or n (%). *P  0.05 vs. the placebo group; †P  0.05 vs. the rosiglitazone group. IHD, ischemic heart disease.
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analyses on macrophages selectively extracted from seven
plaques randomly selected from each of the three groups.
The small sample size used was not sufficient to reach an
adequate statistical power for the comparisons among
groups, so we can only describe the tendency of central
measures for the three groups. However, we observed that
the placebo group had the highest of both ubiquitin levels
(457.9
 99 ng/mg) and proteasome 20S activity (76.3
 22
pmol/mg); the nondiabetic group had the lowest levels
(ubiquitin 237 
 78 ng/mg, proteasome 20S 27.6 
 6
pmol/mg), and rosiglitazone had intermediate levels (ubiq-
uitin 339
 89 ng/mg, proteasome 20S 41.9
 12 pmol/mg).
Colocalization of proteasome 20S and ubiquitin with
macrophages in diabetic plaques. Serial sections of
diabetic plaques were incubated with the primary antibod-
ies anti-ubiquitin, anti–proteasome 20S, and anti-CD68.
The expression of both ubiquitin and proteasome 20S were
associated with CD68 macrophages in plaque sections
(Fig. 4). Thus, these analyses confirmed the concomitant
presence of ubiquitin and proteasome 20S in macrophages
of diabetic plaque.
NF-B activity. NF-B activation, as reflected by the
selective analysis of the activated form of both p50 and
p65, was significantly higher in both placebo (P  0.01)
and rosiglitazone (P  0.01) inflammatory cells than in
nondiabetic macrophages. In plaques from diabetic pa-
tients, both p50 (P  0.01) and p65 (P  0.001) were
significantly higher in placebo-treated than in rosiglita-
zone-treated patients. Immunohistochemistry and quanti-
tative analyses revealed lower staining and levels for IB-
in diabetic inflammatory cells than in nondiabetic inflam-
matory cells (placebo P  0.01, rosiglitazone P  0.001).
Moreover, both staining for and levels of IB- were
higher in rosiglitazone than in placebo plaques (Fig. 5).
Quantification of oxidative stress. Higher nitrotyrosine
levels were found in diabetic plaques than in nondiabetic
plaques (diabetic placebo 3.4 
 0.43 nmol/pg, diabetic
rosiglitazone 2.4 
 0.23 nmol/pg, nondiabetic group 1.2 

0.31 nmol/pg, P  0.001). A similar pattern was found for
O2
 production (diabetic placebo 6.22 
 1.5 pmol/l, diabetic
rosiglitazone 3.87
 1.2 pmol/l, nondiabetic group 2.34
 0.98
pmol/l, P  0.01). In diabetic patients, nitrotyrosine levels
and O2
 production were significantly higher in plaques from
placebo-treated than in rosiglitazone-treated patients (ni-
trotyrosine 3.4
 0.43 vs. 2.4
 0.23 nmol/pg, P 0.01; O2

6.22 
 1.5 vs. 3.87 
 1.2 pmol/l, P  0.01).
In vitro study. Monocytes from diabetic patients evi-
denced higher levels of ubiquitin, p50, p65, and O2

production, as well as higher proteasome 20S, along with
a lesser IB- levels compared with monocytes from
nondiabetic patients (P  0.01). Levels of ubiquitin, p50,
p65, and O2
 production, as well as proteasome 20S
activity, were significantly lower in the diabetic monocytes
incubated with rosiglitazone than in diabetic monocytes
incubated without rosiglitazone (P  0.01), whereas IB-
levels were significantly higher in the diabetic monocytes
incubated with rosiglitazone than in diabetic monocytes
incubated without rosiglitazone (P  0.01) (Fig. 6). Levels
of p50 and p65 levels were significantly lower in the
diabetic monocytes incubated with MG132 than in those
incubated without MG132 (p50 16.8 
 1.3 vs. 20 
 1.6
ng/mg, P  0.01; p65 25 
 3.2 vs. 30.4 
 1.5 ng/mg, P 
0.01), whereas IB- (32.8 
 8.7 vs. 19 
 2.4 ng/mg, P 
0.01) was significantly higher in the diabetic monocytes
incubated with MG132 than in those incubated without
MG132. Although ubiquitin levels were higher in mono-
cytes incubated with MG132, there were not statistically
significant differences among the groups (434.7 
 38.5 vs.
410 
 44.4 ng/mg, P  0.2).
DISCUSSION
This study shows that ubiquitin-proteasome system over-
activity is associated with the inflammatory process of
atherosclerotic plaques of type 2 diabetic patients. In
particular, the ubiquitin-proteasome activity was greater in
diabetic atherosclerotic lesions as compared with nondia-
betic lesions, and it was associated with higher NF-B and
MMP-9 levels along with less interstitial collagen content.
All this might increase the risk of future acute ischemic
events precipitated by inflammatory-dependent rupture of
atherosclerotic plaques. Moreover, we provide evidence
that the PPAR- agonist rosiglitazone may prevent plaque
progression to an unstable phenotype in diabetic patients
by reducing ubiquitin-proteasome activity.
A previous postmortem study (18) has reported en-
hanced ubiquitin expression in unstable coronary
plaques. However, the study did not provide any evi-
dence about ubiquitin expression in subgroups of high-
risk plaques, such as those found in diabetic patients, or
assess the specific pathway transducing environmental
stimuli in ubiquitin-proteasome overexpression. In our
study, macrophages, T-cells, and HDLA-DR inflamma-
tory cells were more abundant in diabetic plaques and
represented the major source of ubiquitin-proteasome
activity, suggesting the presence of an active inflamma-
tory reaction in diabetic plaques. Concomitantly higher
expression of ubiquitin and proteasome was found in
human plaque macrophages obtained from the asymp-
tomatic carotid lesions of patients with type 2 diabetes
compared with nondiabetic lesions. In agreement with
the difference in ubiquitin-proteasome staining pattern,
the histological milieu of the lesions appears different
with regard to cellularity, but not in the degree of vessel
stenosis, suggesting that diabetic and nondiabetic le-
sions are only different in regard to inflammatory bur-
den. These data are consistent with previous findings
that the inflammatory response was greater in diabetic
TABLE 2
Metabolic parameters of diabetic patients after rosiglitazone and
placebo treatments
Variables Placebo group Rosiglitazone group
n 23 23
BMI (kg/m2) 27.9
 7 29.1 
 5
Systolic blood pressure
(mmHg) 126
 13 126
 15
Diastolic blood pressure
(mmHg) 82
 6 80 
 4
A1C (%) 7.3
 1.5 7.3
 1.8
Blood glucose (mmol/l) 8.1
 1.7* 8.1
 1.9*
Insulin (U/ml) 10.6
 2.7 10.4
 2.9
HOMA-IR 4.47
 1.5 3.51
 1.2*†
CRP (mg/dl) 1.1
 0.07 0.77
 0.09*†
Total cholesterol
(mmol/l) 5.61
 0.11 5.69
 0.14
HDL cholesterol
(mmol/l) 1.24
 0.09 1.29
 0.1
Triglycerides (mmol/l) 1.85
 0.32 1.89
 0.36
Data are means 
 SD. *P  0.05 vs. baseline data; †P  0.05 vs. the
placebo group.
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FIG. 2. A: Representative sections show immunochemistry for CD68, CD3, and HLA-DR in nondiabetic, placebo-treated, and rosiglitazone-treated
diabetic plaques. The boxes show the immunochemistry at low magnification. B: ELISA for MMP-9, TNF-, and sirius red staining for collagen
content in nondiabetic, placebo-treated, and rosiglitazone-treated diabetic plaques. (The boxplots show the median, 25th, and 75th percentiles,
range, and extreme values.) C: Representative sections show immunochemistry for MMP-9, TNF-, and sirius red staining for collagen content
in nondiabetic, placebo-treated, and rosiglitazone-treated diabetic plaques. The boxes show the immunochemistry at low magnification. Similar
regions of plaque are shown. These results are typical of nondiabetic, placebo-treated, and rosiglitazone-treated diabetic plaques. *P < 0.05 vs.
the placebo group; †P < 0.05 vs. the rosiglitazone group.
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than in nondiabetic plaques (17). Moreover, an associa-
tion between RAGE-expressing macrophages and up-
regulation of inflammatory NF-B, COX-2/mPGES-1, and
MMPs has been shown in carotid arteries of diabetic
patients (17). Finally, a recent postmortem study (19)
demonstrates an increase in apoptotic macrophages and
smooth muscle cells in coronary arteries of diabetic
patients, which may be related to necrotic core expan-
sion, thinning of the fibrous cap, and plaque instability.
Hence, the differences in plaque behavior likely stem
FIG. 3. A: Levels of proteasome 20S by a specific SDS activation kit and ubiquitin levels by an ELISA kit. B: Proteasome 20S and ubiquitin by
immunohistochemistry in nondiabetic, placebo-treated, and rosiglitazone-treated diabetic plaques. The boxes show the immunochemistry at low
magnification. C: Negative control. Similar regions of the plaque are shown. These results are typical of nondiabetic, placebo-treated, and
rosiglitazone-treated diabetic plaques. *P < 0.05 vs. the placebo group; †P < 0.05 vs. the rosiglitazone group.
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from differences in the presence of stimuli (i.e., oxida-
tive stress, as evidenced by high O2
 production and
nitrotyrosine levels) for selective expression of ubiq-
uitin-proteasome, capable of disrupting plaque stability
via NF-B induction.
NF-B is normally bound to IB in the cytosol; this
binding prevents its movement into the nucleus (20).
Various cellular stimuli, such as oxidative stress, induce
ubiquitination of phosphorylated IBs and subsequent
degradation by the proteasome (21). Degradation of IBs
results in unmasking of the nuclear localization signal of
NF-B dimers, which subsequently translocates to the
nucleus, where it induces the transcription of proinflam-
matory cytokines that play a central role in plaque insta-
bility progression, like TNF- (22,23). Our findings also
suggest that diabetes may induce phosphorylation and
degradation of IBs via the ubiquitin-proteasome overac-
tivity, thus enhancing NF-B activation. Previous reports
evidenced the involvement of the ubiquitin-proteasome
system in NF-B activation, particularly under conditions
of aggravated oxidative stress. Oxidative stress is the
common factor underlying insulin resistance, type 2 dia-
betes, and cardiovascular disease and may explain the
presence of inflammation in each of these conditions (24).
Although it is well recognized that inflammation is one
manifestation of oxidative stress, and the pathways that
generate the mediators of inflammation, such as interleu-
kins, are all induced by oxidative stress (25), the mecha-
nism by which oxidative stress may be involved in
inflammatory process of type 2 diabetic plaques is not fully
clarified. In this context, our data suggest a novel mecha-
nism by which oxidative stress, increasing ubiquitin-pro-
teasome activity, may mediate inflammatory activity in
diabetic atherosclerotic plaques. Of note, it has been
shown that oxidative stress can stimulate the ubiquitin
system in macrophages by inducing the expression of
components of its enzymatic machinery, such as ubiquitin-
binding proteins (26,27). Accordingly, in cultured mono-
cytes from diabetic patients, we evidenced that O2

production, as well as ubiquitin-proteasome activity and
NF-B levels, were significantly higher when compared
with nondiabetic patients. Thus, we can speculate that
increased ubiquitin-proteasome activity in plaque macro-
phages, as a consequence of oxidative stress overexpres-
sion, may enhance the synthesis of NF-B in the same cell,
possibly representing a crucial step in the pathophysiology
of diabetic plaque instability. Because of the study design,
we cannot exclude whether the ubiquitin-proteasome
pathway exerts also a protective compensatory response
(28), or whether it is merely a correlative marker for the
presence of inflammatory cells in diabetic lesions. How-
ever, the concomitant presence of ubiquitin and protea-
some 20S in diabetic macrophages, as well as the
reduction of NF-B levels in diabetic monocytes treated
with proteasome inhibitor, suggests that the ubiquitin-
proteasome pathway may have a proinflammatory effect in
diabetic individuals. Moreover, higher expression of ubiq-
uitin-proteasome and MMP-9 in diabetic lesions, one of the
most important enzymes in the process of atherosclerotic
plaque rupture (29), along with a lesser interstitial colla-
gen content, suggests an involvement of the ubiquitin
proteasome system in instability of diabetic lesion by
increasing plaque erosion.
The present findings also show an inhibitory effect of
rosiglitazone on ubiquitin-proteasome activity in diabetic
lesions. Indeed, at the same level of blood glucose levels,
diabetic patients treated with rosiglitazone had the lowest
level of ubiquitin and proteasome 20S activity, plaque
inflammatory cells, cytokines, oxidative stress, and MMP-9
associated with the highest content of plaque interstitial
collagen. Thus, patients assigned to rosiglitazone had
lesser plaque progression to an unstable phenotype than
patients assigned to placebo. In particular, the reduced
ubiquitin-proteasome activity seen in diabetic plaques of
the rosiglitazone group suggests decreased IB degrada-
tion and hence NF-B activation. All this may have clinical
implications because in a large series of carotid endarter-
ectomy specimens, it has been shown that plaque inflam-
mation is one of the major determinants of ischemic
events in patients affected by carotid atherosclerotic dis-
ease (30). Sufficient data in humans suggest that PPAR-
agonists reduce common carotid arterial intima media
thickness progression as well as circulating markers of
inflammation as early as 3 months after the administration
in both nondiabetic and diabetic patients (8,12). Moreover,
there is accumulating data to suggest that PPAR- agonists
exert anti-inflammatory and antioxidant effects, including
decreases of cytokines and MMPs in monocytes, macro-
phages, T-cells, and vascular smooth muscle cells (31–35).
In line with this evidence, we observed a significant
reduction of CRP serum levels in diabetic patients treated
with rosiglitazone. Although PPAR- agonists may inhibit
proteasome activity in human cancer (36), until now there
was no evidence that this effect was reproducible in
human atherosclerotic plaques. The hypothesis that
plaque ubiquitin-proteasome activity is reduced by PPAR-
agonists is also supported by our “in vitro experiments”
that evidenced a reduction of ubiquitin-proteasome activ-
ity, NF-B levels, and O2
 production associated with a
significant increment of IB-, in monocytes from diabetic
patients treated with rosiglitazone. The mechanism of
repression of the proteasome by rosiglitazone remains a
FIG. 4. Diabetic plaque sections show that
ubiquitin and proteasome 20S colocalize with
macrophage immunoreactivity.
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FIG. 5. A: Levels of activated NF-B (specific Trans-AM p50 and p65 subunit assay kit) and IB- in nondiabetic, placebo-treated, and
rosiglitazone-treated diabetic plaques. B: Representative sections show immunohistochemistry for activated p65 and p50 and IB-. The boxes
show the immunochemistry at low magnification. C: Negative control. Similar regions of the plaque are shown. These results are typical of
nondiabetic, placebo-treated, and rosiglitazone-treated diabetic plaques. *P < 0.05 vs. the placebo group; †P < 0.05 vs. the rosiglitazone group.
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mystery and requires further studies. On the other hand,
the reduction in O2
 production by monocytes after
rosiglitazone treatment may allow a lower polyubiquitina-
tion, as evidenced by a reduction in ubiquitin levels. We
therefore speculated that proteasome reduction by rosigli-
tazone may be induced by inhibition of oxidative stress
FIG. 6. Ubiquitin, proteasome 20S, activated NF-B, and IB- in diabetic and nondiabetic monocytes. Purified diabetic monocytes were cultured
in the presence or absence (48 h) of rosiglitazone (7.0 mol/l). *P < 0.05 vs. the placebo group; †P < 0.05 vs. the rosiglitazone group.
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and polyubiquitination. Rosiglitazone treatment also pro-
duced a significant reduction in insulin-resistance, as
indicated by reduced HOMA-IR levels. As insulin resis-
tance is associated with increased cardiovascular and
cerebrovascular risk (37), improved insulin sensitivity may
be one mechanism by which rosiglitazone retards athero-
genesis progression. On the other hand, oxidative stress
has been shown to induce insulin resistance through
NF-B activation (38). In this perspective, rosiglitazone, by
reducing oxidative stress and ubiquitin-proteasome activ-
ity, may enhance both insulin sensitivity and diabetic
plaque stability. We also do not exclude the possibility that
rosiglitazone inhibits NF-B activation through additional
mechanisms independent of PPAR-. Indeed, a PPAR-–
independent pathway may be operative in neuronal cells
via inhibition of inducible nitric oxide synthase (39).
Furthermore, PPAR- agonists inhibit the nuclear translo-
cation and subsequent DNA binding of NF-B via an
IB–dependent pathway by inhibiting the immune respon-
se–induced degradation of IBs (40). This provides evi-
dence that a component of the anti-inflammatory effect is
mediated by the action of PPAR- agonists on the systemic
immune system. Although further investigation will be
required to elucidate the upstream mechanisms by which
PPAR- inhibits the degradation of IBs, inhibition of
cytokine gene expression suggests that activation of
PPAR- may alter functional elements common to both of
these pathways.
This study demonstrates enhanced ubiquitin-protea-
some activity in diabetic atherosclerotic lesions, and it
provides evidence that the activation of this system by
inflammatory cells is associated with an NF-B–depen-
dent increase in inflammation, potentially promoting
plaque rupture. Moreover, we hypothesize that thiazolod-
inediones may reduce NF-B activation by modulation of
ubiquitin-proteasome activity in human atherosclerotic
lesions of diabetic patients.
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